Comprehensive Study of Vancomycin and Piperacillin/Tazobactam induced Acute Kidney Injury

Abstract

Background: Acute kidney injury is increasingly being seen in primary care in people without any acute illness, and awareness of the condition needs to be raised among primary care health professionals. Aim of the Work: to discuss comparison of the incidence of Vancomycin and Piperacillin/Tazobactam induced Acute Kidney Injury in hospitalized patients, especially critically ill patients with Acute Broncho-Pneumonia. Efficacy of renal replacement therapy will be evaluated. Patients and Methods: This prospective study included 75 adult patients ≥18 years of age admitted to ICU with broncho-pneumonia and normal kidney functions. All patients were divided into 3 groups; the first group consisted of 25 patients who received Vancomycin as monotherapy, the second group consisted of 25 patients who received Piperacillin/Tazobactam as monotherapy, and the third group consisted of 25 patients who received combined Vancomycin/Piperacillin. Results: regarding incidence of AKI there was only 1 case (4%) of Vanc. group who developed AKI, while there were another 4 cases (16%) of Piptazo. group and 6 cases (24%) of comb V/P group who developed AKI (p=0.100). Conclusion: there are an-increased odds for acute kidney injury associated with combination vancomycin and piperacillin/tazobactam compared to vancomycin monotherapy and piperacillin/tazobactam monotherapy.